The White House announced on Thursday that 48 drugs will be subject to penalties after drugmakers raised prices faster than the rate of inflation.
Under President Joe Biden’s Inflation Reduction Act (IRA), drug companies that price gouge may be required to pay rebates to Medicare, particularly focusing on those affecting over 750,000 seniors who rely on Medicare Part B drugs.
The rebates, effective in January, are expected to result in savings for seniors ranging from $1 to $2,786 per dose.
“President Biden’s prescription drug law cracks down on price gouging from Big Pharma, requiring companies to pay back Medicare if they raise prices on seniors at a higher rate than inflation,” the White House said in a statement….
White House Cracks Down on Big Pharma: 48 Drugs Face Penalties for Price Gouging
In a major victory for seniors and advocates fighting against rising drug prices, the White House announced on Thursday that 48 drugs will be subject to penalties under President Biden’s Inflation Reduction Act (IRA). These drugs were identified as having price increases exceeding the rate of inflation, a practice known as price gouging.
What the IRA Means for Seniors:
The IRA includes a provision that empowers the federal government to penalize drugmakers who raise prices on Medicare Part B drugs faster than inflation. This is particularly significant for over 750,000 seniors who rely on these medications.
How Penalties Work:
Under the new regulations, drug companies that engage in price gouging will be required to pay rebates to Medicare. These rebates will be calculated based on the difference between the actual price increase and the inflation-adjusted price. The estimated savings for seniors range from $1 to $2,786 per dose, a substantial relief for many who struggle to afford their medications.
A List of Affected Drugs:
The White House has released a list of the 48 drugs identified for price gouging penalties. Some of the notable medications on the list include:
- Advair Diskus (fluticasone propionate/salmeterol) for asthma
- Humira (adalimumab) for rheumatoid arthritis and Crohn’s disease
- Enbrel (etanercept) for psoriasis and psoriatic arthritis
- Januvia (sitagliptin) for type 2 diabetes
- Xarelto (rivaroxaban) for blood clots
Impact on Big Pharma:
This move by the White House is a significant blow to Big Pharma, which has long been criticized for its high drug prices. The IRA’s price gouging penalties are expected to cost drug companies billions of dollars in lost revenue.
A Step in the Right Direction:
While the IRA’s price gouging penalties are a positive step, advocates argue that more needs to be done to address the issue of rising drug prices. They call for reforms such as allowing Medicare to negotiate drug prices directly with manufacturers and capping the annual price increases for all medications.
Here are some additional details about the IRA’s price gouging penalties:
- The penalties will be applied starting in January 2024.
- The Department of Health and Human Services (HHS) will be responsible for determining which drugs are subject to penalties.
- Drug companies can appeal the penalties to the HHS.
- The penalties are expected to generate billions of dollars in savings for Medicare, which will be used to fund other healthcare programs.
Looking Ahead:
The IRA’s price gouging penalties are a major victory for seniors and a step in the right direction towards addressing the issue of rising drug prices. However, more work remains to be done to ensure that all Americans have access to affordable medications.
